Literature DB >> 28697952

Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.

Tarun Ojha1, Vertika Pathak2, Yang Shi2, Wim E Hennink3, Chrit T W Moonen4, Gert Storm5, Fabian Kiessling6, Twan Lammers7.   

Abstract

The performance of nanomedicine formulations depends on the Enhanced Permeability and Retention (EPR) effect. Prototypic nanomedicine-based drug delivery systems, such as liposomes, polymers and micelles, aim to exploit the EPR effect to accumulate at pathological sites, to thereby improve the balance between drug efficacy and toxicity. Thus far, however, tumor-targeted nanomedicines have not yet managed to achieve convincing therapeutic results, at least not in large cohorts of patients. This is likely mostly due to high inter- and intra-patient heterogeneity in EPR. Besides developing (imaging) biomarkers to monitor and predict EPR, another strategy to address this heterogeneity is the establishment of vessel modulation strategies to homogenize and improve EPR. Over the years, several pharmacological and physical co-treatments have been evaluated to improve EPR-mediated tumor targeting. These include pharmacological strategies, such as vessel permeabilization, normalization, disruption and promotion, as well as physical EPR enhancement via hyperthermia, radiotherapy, sonoporation and phototherapy. In the present manuscript, we summarize exemplary studies showing that pharmacological and physical vessel modulation strategies can be used to improve tumor-targeted drug delivery, and we discuss how these advanced combination regimens can be optimally employed to enhance the (pre-) clinical performance of tumor-targeted nanomedicines.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disruption; Drug delivery; EPR; Hyperthermia; Nanomedicine; Normalization; Permeabilization; Phototherapy; Promotion; Radiotherapy; Sonoporation; Tumor targeting

Mesh:

Substances:

Year:  2017        PMID: 28697952      PMCID: PMC5919100          DOI: 10.1016/j.addr.2017.07.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  102 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 2.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

3.  Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.

Authors:  Ana M Ponce; Benjamin L Viglianti; Daohai Yu; Pavel S Yarmolenko; Charles R Michelich; Janet Woo; Marcel B Bally; Mark W Dewhirst
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

Review 4.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

5.  Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Authors:  Tracy T Batchelor; Elizabeth R Gerstner; Kyrre E Emblem; Dan G Duda; Jayashree Kalpathy-Cramer; Matija Snuderl; Marek Ancukiewicz; Pavlina Polaskova; Marco C Pinho; Dominique Jennings; Scott R Plotkin; Andrew S Chi; April F Eichler; Jorg Dietrich; Fred H Hochberg; Christine Lu-Emerson; A John Iafrate; S Percy Ivy; Bruce R Rosen; Jay S Loeffler; Patrick Y Wen; A Greg Sorensen; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

6.  Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.

Authors:  Margaret Folaron; James Kalmuk; Jaimee Lockwood; Costakis Frangou; Jordan Vokes; Steven G Turowski; Mihai Merzianu; Nestor R Rigual; Maureen Sullivan-Nasca; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh; Mukund Seshadri
Journal:  Oral Oncol       Date:  2013-07-23       Impact factor: 5.337

7.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

8.  Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.

Authors:  Q-S Ng; H Mandeville; V Goh; R Alonzi; J Milner; D Carnell; K Meer; A R Padhani; M I Saunders; P J Hoskin
Journal:  Ann Oncol       Date:  2011-07-15       Impact factor: 32.976

9.  Image-guided drug delivery: preclinical applications and clinical translation.

Authors:  Tarun Ojha; Larissa Rizzo; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Expert Opin Drug Deliv       Date:  2015-06-17       Impact factor: 6.648

10.  Selective permeabilization of the blood-brain barrier at sites of metastasis.

Authors:  John J Connell; Grégoire Chatain; Bart Cornelissen; Katherine A Vallis; Alastair Hamilton; Len Seymour; Daniel C Anthony; Nicola R Sibson
Journal:  J Natl Cancer Inst       Date:  2013-10-09       Impact factor: 13.506

View more
  46 in total

Review 1.  Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.

Authors:  Huan Meng; Andre E Nel
Journal:  Adv Drug Deliv Rev       Date:  2018-06-26       Impact factor: 15.470

2.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 3.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

4.  Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer.

Authors:  Shreya Goel; Carolina A Ferreira; Prashant Dogra; Bo Yu; Christopher J Kutyreff; Cerise M Siamof; Jonathan W Engle; Todd E Barnhart; Vittorio Cristini; Zhihui Wang; Weibo Cai
Journal:  Small       Date:  2019-09-29       Impact factor: 13.281

Review 5.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 6.  Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.

Authors:  Madeline T Olson; Quan P Ly; Aaron M Mohs
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

Review 7.  Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting.

Authors:  Jessica F Liu; Bian Jang; David Issadore; Andrew Tsourkas
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-26

8.  A quantitative in silico platform for simulating cytotoxic and nanoparticle drug delivery to solid tumours.

Authors:  Peter A Wijeratne; Vasileios Vavourakis
Journal:  Interface Focus       Date:  2019-04-19       Impact factor: 3.906

9.  Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Yuhao Wang; Hongjun Wang
Journal:  Adv Ther (Weinh)       Date:  2019-09-30

10.  Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors.

Authors:  Benjamin Theek; Maike Baues; Felix Gremse; Robert Pola; Michal Pechar; Inka Negwer; Kaloian Koynov; Benjamin Weber; Matthias Barz; Willi Jahnen-Dechent; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  J Control Release       Date:  2018-05-04       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.